drugset / Trial / NCT07559331

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

NCT07559331

Phase 3 Recruiting 86 enrolled Shandong University
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized controlled study of high-dose Dexamethasone combined with Orelabrutinib versus high-dose Dexamethasone combined with placebo in adult patients with newly diagnosed Primary Immune Thrombocytopenia.

Timeline

Start
2026-04-08
Primary completion
2027-04-08
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Orelabrutinib Small molecule 50 mg
Background Dexamethasone Small molecule 40 mg